Summary & Overview
HCPCS Level II J9151: Daunorubicin Citrate Liposomal Injection, 10 mg
HCPCS Level II code J9151 designates a 10 mg vial of liposomal daunorubicin citrate used in chemotherapy regimens. As a single-supply drug code for an antineoplastic agent, it matters nationally because it is tied to oncology treatment episodes, hospital outpatient infusion billing, and specialty drug spend. Accurate coding affects medical record fidelity, payer adjudication, and cost reporting for complex cancer care.
Key payers commonly engaged with this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a focused review of code definition and clinical context, payer coverage considerations, and typical site-of-service usage. The publication summarizes benchmarks where available, highlights common billing patterns for parenteral oncology drugs, and outlines policy and documentation themes that influence claim processing.
This summary is intended to orient clinicians, billing teams, and policy analysts to the clinical role of the medication, the settings where the code is most often used, and the payer landscape relevant to claims and reimbursement workflows. Data not available in the input will be noted in specific sections of the full publication.
Billing Code Overview
HCPCS Level II code J9151 represents an injection of daunorubicin citrate, liposomal formulation, 10 mg. This entry-level drug code is used to report administration of the specified chemotherapy agent.
Service Type: Intravenous chemotherapy administration
Typical Site of Service: Hospital outpatient infusion center, specialty oncology clinics, or ambulatory infusion centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old with relapsed or refractory acute myeloid leukemia (AML) or other hematologic malignancy for which liposomal daunorubicin is indicated. The patient presents to an outpatient oncology infusion center or hospital-based oncology unit for chemotherapy administration. Prior to infusion, the oncology team verifies diagnosis, reviews recent labs (CBC with differential, renal and hepatic function), confirms vascular access (peripheral IV or implanted port), and performs a pre-medication assessment. The liposomal formulation of daunorubicin is prepared by pharmacy in a sterile compounding environment, labeled as J9151 per 10 mg vial dosing, and delivered to the infusion nurse. During administration, nursing monitors vitals, infusion site, and for infusion-related reactions; cardiotoxicity risk is considered and baseline or interval echocardiography and prior cumulative anthracycline dose are reviewed. After infusion, the patient is observed per protocol for immediate adverse events, provided with post-infusion instructions, and scheduled for follow-up visits to assess response, toxicity, and laboratory monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when administration required significantly more work due to complexity (document rationale). |